JonesTrading analyst Debanjana Chatterjee reiterated a Buy rating on EyePoint Pharmaceuticals (EYPT – Research Report) today and set a price target of $45.00.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Debanjana Chatterjee’s rating is based on the view that the current market reaction to EyePoint Pharmaceuticals’ recent data release is exaggerated. The 24-week data aligned with expectations, showing similar efficacy trends as seen in the previous 16-week results. Despite initial concerns due to an incomplete press release, detailed information provided later indicated no significant issues, with Duravyu showing non-inferiority to Eylea.
Additionally, there are concerns regarding further financing for their pivotal programs in diabetic macular edema (DME) and wet age-related macular degeneration (AMD). However, EyePoint appears to be financially equipped to support these initiatives, particularly if the FDA allows a streamlined approach. The undervaluation of Duravyu’s potential in both wet AMD and DME presents a buying opportunity, especially ahead of important catalysts such as FDA meetings and study completions anticipated in the coming years.